Royalty Report: Medical, Coating, Device – Collection: 299236

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Medical
  • Coating
  • Device
  • Drugs
  • Stent
  • Chemicals
  • Biotechnology
  • cardiac
  • Delivery
  • Surgical
  • Cancer
  • Disease
  • Therapeutic
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299236

License Grant
Under the initial agreement, the Canadian Licensor agreed to license on a co-exclusive certain patent rights, license rights, and technology.

This agreement is extending Licensee’s worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Licensor Technology in the Peripheral Vascular Field of Use and the GI Field of Use.

Licensor newly grants its licensee, the right for Licensee to have third party Distributors distribute Eligible Peripheral Vascular and/or GI Products.

This agreement is co-exclusive with an option to become exclusive.

License Property
This agreement is for paclitaxel or certain other agents as a coating for certain medical devices.

The license agreement regards paclitaxel-eluting stent products and related technologies.  Paclitaxel is released from the balloon or stent to prevent scar tissue formation in the blood vessel that can re-obstruct the artery (restenosis).

Field of Use
As used herein, the Coronary Vascular Field of Use means endoluminal vascular Licensed Applications for the treatment and/or prevention of disease of the coronary arteries and their branches, or other vasculature providing blood flow to the heart.

As used herein, the Peripheral Vascular Field of Use means the endoluminal vascular licensed applications for the treatment or preventionof disease of the peripheral blood vessels of the body.  Notwithstanding the foregoing, Peripheral Vascular Field of Use excludes any application in the Coronary Vascular Field of Use.  

GI Field of Use means the endoluminal licensed applications for the treatment or prevention of disease of the alimentary tract or liver.

IPSCIO Record ID: 209508

License Grant
Licensor, of the Netherlands, grants a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensees Stents utilizing, incorporating or coated with Licensors Drug/Polymer Composite Formulation, Biolimus A9 and/or Licensors Polymer Coating in Licensees Licensed Field of Use; and

At Licensees option, a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.

License Property
The Coated Stents means Licensees Stents marketed, developed or sold by Licensee and coated with Licensors Polymer Coating, Occams Drug/Polymer Composite Formulation, or Biolimus A9.

The Covered Products means either or both Coated Stents and Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.

The patents relate to Endovascular Stents and coatings.

Biolimus A9 is formulated to inhibit excessive tissue formation around the stent following implantation, a common side effect called restenosis which often threatens to reverse the clinical benefits of the angioplasty and stent implantation procedures.

Field of Use
Licensees Licensed Field of Use means any applications, procedures, processes or other uses related to drug-eluting, commonly delivered Stents that are delivered as a series of short stents on a delivery catheter wherein the operator has the ability to select the number of short stents as a portion of the total number of stents in the series to be deployed, solely for use in coronary and peripheral vascular applications.

In Japan, Licensees Licensed Field of Use is further limited to treating long lesions, multiple vessels or small vessels in coronary and peripheral applications.

IPSCIO Record ID: 5512

License Grant
The Licensor hereby grants to the Licensee the exclusive worldwide license for certain patented technologies marketed under the trade names PROstent (TM) and Liprostin / PROstent (TM), and the Licensor's referenced technologies with multiple stent coating applications for use with other medical devices, including catheter delivery of PROstent.
License Property
The technology being licensed includes Patent Application No. 09/309,949; Filed on May 11, 1999; 'Prosthesis With Biodegradable Surface Coating and Method For Making Same.' This application is a continuation-in-part application of U.S. Patent Application Serial No. 08/797,743 filed on February 7, 1997.
Abstact A vascular structure includes suitable mechanical properties needed to open and maintain a vessel, duct, tract, or organ and precise chronicity controlling the release and delivery of a bioactive agent carried on the vascular structure. The bioactive agent is capable of acting upon and altering the mechanisms of biologic systems in a manner providing a medicinal therapy. The vascular structure includes at least one layer or coating of the bioactive agent overlaid by a permiable membrane for controlling the osmotic release of the bioactive agent.

Technology also includes Patent Application Serial No. 08/797,743; Filed on February 7, 1997; 'Composition and Method For Making a Biodegradable Drug Delivery Stent'.  Licensee is from Canada and licensor from U.S.
Abstract A stent or vascular graft for supporting a blood vessel or organ lumen is coated with a biodegradable, resorbable and hemocompatible surface substrate. Biologically active microspheres which controllably release the biologically active agent into the vessel wall or organ to inhibit restenosis of the stent is embedded in the stent substrate. The biologically active microspheres include encapsulated PGE1 in a water soluble polyethylene glycol mix, which over a period of time dissolves and releases the PGE1 into the vessel wall or organ.

USE OF TRADEMARKS. The Licensee will be allowed to use any and all trademarks of the Licensor with respect to the Technology, Products and any Improvements.

IPSCIO Record ID: 493

License Grant
The Company hereby grants to Licensee an exclusive (subject only to the rights granted to BSC) worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Company Technology in the Licensed Field of Use solely for use in the Licensed Applications.
License Property
The Company has also developed and owns certain products and technology in the area of the use of paclitaxel as a coating for certain medical devices.

Licensed Application shall means the use of the Company Technology in the Licensed Field of Use on or incorporated in Stent Products and Endoluminal Products, but specifically excluding systemic treatments and pastes, micropheres, films, sprays and similar formulations in circumstances where such are not applied to or incorporated in either a Stent Product or an Endoluminal Product, as the case may be.

Field of Use
'Licensed Field of Use' means endoluminal vascular and GI applications.

IPSCIO Record ID: 248402

License Grant
Licensor grants the sole and exclusive right, license and privilege to use the License Rights in the Application Field, and to manufacture and sell, and to grant sublicenses to others to use, manufacture and sell, Products in the Territory.
License Property
Licensor possesses proprietary technology with respect to nitinol stents for vascular and non-vascular applications.

License Rights shall mean all of NMTs rights to Product Developments, Patent Rights and Technical Information in the Application Field.

Field of Use
Licensee possesses proprietary technology with respect to catheters and other products useful in the delivery and placement of Stents and related applications

Application Field shall mean the entire field of stents, whether vascular or non-vascular, covered or uncovered, coated or uncoated, and applications therefor.

IPSCIO Record ID: 698

License Grant
The Company hereby grants to Licensee an exclusive (subject only to the rights granted to CI) worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Angiotech Technology in the Licensed Field of Use solely for use in the Licensed Applications (the 'BSC License').
License Property
Licensor owns certain domestic and foreign patents and patent applications and has acquired licenses to other domestic and foreign patents and patent applications relating to the use of paclitaxel as a coating for certain medical devices.

Licensor has also developed and owns certain products and technology in the area of the use of paclitaxel as a coating for certain medical devices.

Licensor has the right to grant licenses with respect to such patents, patent applications, products and technology for use in specified areas; and each Licensee desires to receive a co-exclusive license, subject only to the grant of such a license to the other party, for the use of such patents, patent applications, products and technology for the duration of the United States and foreign patents covering such products and technology for certain applications in the fields of vascular and alimentary tract and liver applications, and Licensor is willing to grant such a license to each Licensee.

Field of Use
Licensed Field of Use means endoluminal vascular and GI applications.

IPSCIO Record ID: 530

License Grant
Licensor will grant Licensee an exclusive (even as to Licensor), worldwide, fully-paid, perpetual license (with the right to sublicense) under Licensor’s interest in any Collaboration Technology jointly owned by Licensor and Licensee necessary or useful to make, have made, import, use, offer for sale and sell Development Candidates (and corresponding Collaboration Products), subject to Article 15, for indications other than those which Licensor retains rights hereunder, and products other than Collaboration Products.
License Property
Collaboration Products refer to research, develop and commercialize gene-based products incorporating the VEGF gene for the treatment of coronary artery disease and peripheral vascular disease.  VEGF is a protein that stimulates the formation of new blood vessels and improves blood flow.
Field of Use
Field shall mean the research, drug discovery and development collaboration aimed at therapeutic agents useful for Gene Therapy-based induction of angiogenesis and for the first two years of the Research Program shall include all clinical indications; provided, thereafter the Field shall be limited to the treatment of coronary artery disease (CAD) and/or peripheral vascular disease (PVD) and/or those other specific clinical indications selected by Licensor pursuant to Section 2.5 below.

IPSCIO Record ID: 222533

License Grant
Licensor grants to Licensee, a separate worldwide license under Licensor’s Patent Rights and Know-how to make, have made for it only by a properly sublicensed Manufacturer as set forth herein, use, import, and sell that Licensed Product. The license granted herein is expressly limited to the specific Licensed Products defined herein, and does not include the right to sublicense except as set forth.  All licenses granted by Licensor to Licensee under this Agreement are non-exclusive unless specifically stated otherwise for a particular Licensed Product.
License Property
Licensed Products means each of the separately sold Medical Products that bear a Hemocompatable Coating and a Drug Delivery Coating.

Medical Products means the vessel connector and flow-limiter components of a surgically implanted graft prosthetic system for coupling vascular members in the coronary asculature, such as the vessel connector and flow-limiter components of the devices in the illustrations in U.S. Patent 6,241,764 B1.

6,241,764 – Stented grafts for coupling vascular members

Drug-Delivery Coating means chemical compositions comprised of poly(ethylene-co-vinyl acetate) and poly(butyl methacrylate) components for the purpose of releasing Compounds from the chemical composition.

Hemocompatable Coating means chemical coating compositions that contain one or more of the following components photo-reactive polyvinylpyrrolidone copolymer, nonphoto-reactive polyvinylpyrrolidone, photo-reactive heparin, a crosslinking agent known to the parties as PR04, and a compound for promoting polymer-to-metal adhesion and known to the parties as TL03, for the purpose of providing a hemocompatable surface to the Medical Products.

Licensor U.S. Patents

Hemocompatable Coating formulations

1.

METHOD OF IMPROVING THE BIOCOMPATIBILITY OF SOLID SURFACES
U.S. Patent No. 4,973,493 issued 11/27/1990

2.

BIOCOMPATIBLE COATINGS FOR SOLID SURFACES
U.S. Patent No. 4,979,959 issued 12/25/1990

3.

PREPARATION OF POLYMERIC SURFACES VIA COVALENTLY ATTACHING POLYMERS
U.S. Patent No. 5,002,582 issued 3/26/1991

4.

BIOCOMPATIBLE DEVICE WITH COVALENTLY BONDED BIOCOMPATIBLE AGENT
U.S. Patent No. 5,263,992 issued 11/23/1993

5.

SUBSTRATE SURFACE PREPARATION
U.S. Patent No. 5,512,329 issued 4/30/1996

6.

PHOTOACTIVATABLE CROSS-LINKING AGENTS CONTAINING CHARGED GROUPS FOR WATER SOLUBILITY
U.S. Patent No. 6,077,698 issued 06/20/2000

7.

SURFACE COATING AGENTS
U.S. Patent No. 6,278,018 B1 issued 08/21/2001

8.

SURFACE COATING AGENT
U.S. Patent No. 6,603,040B1 issued 8/05/2003

9.

SILANE COATING COMPOSITION
U.S. Patent No. 6,706,408B2 issued 3/16/2004
Drug-Delivery Coating formulations

1.

BIOACTIVE AGENT RELEASE COATING
U.S. Patent No. 6,214,901B1 issued 04/10/2001

2.

BIOACTIVE AGENT RELEASE COATING
U.S. Patent No. 6,344,035B1 issued 02/05/2002

Field of Use
This agreement pertains to coating on medical related devices such as stent.

IPSCIO Record ID: 203356

License Grant
The Irish Licensor grants a license, with rights to sublicense, the Licensor Proprietary Rights to make, have made, use, import, offer for sale, and sell Licensee Devices incorporating Product in the Territory.

Licensee covenants that, it will only manufacture and supply Product to two (2) other Third Parties for incorporation into implantable medical devices for the Field of Use.

License Property
The Product shall mean the bulk form of the compound paclitaxel and/or any compound that is a modification or derivative of the compound paclitaxel that Licensor manufactures at any time during the term of this Agreement.

Paclitaxel is an anti-proliferative drug.  It is an anti-cancer chemotherapy drug.

Field of Use
The Field of Use shall mean the treatment and/or prevention of restenosis, coronary diseases, and/or vascular diseases.

Paclitaxel is used in Licensee's stent.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 27887

License Grant
The Licensee holds an exclusive worldwide License to use, manufacture and sell products covered by the Metricath patent.
License Property
The Metricath System is a catheter-based technology that allows cardiologists to measure arterial size and wall characteristics, select stent and other treatment devices and confirm stent deployment during interventional treatment of coronary and peripheral artery disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.